Oryon Cell Therapies (“Oryon”), a clinical-stage biotechnology company focused on developing autologous neuron replacement ...
Routine early measurement of neurofilament light chain could help improve prediction of cognitive impairment after ...
Routine early measurement of the neurofilament light chain could help improve prediction of cognitive impairment after out-of ...
Measuring neurofilament light chain levels 48 hours after cardiac arrest can predict long-term cognitive impairment, ...
3h
New Biomarker Discovered For Cognitive Symptoms Of Schizophrenia, Could Serve As Drug Target: Study
A study has found a new biomarker of schizophrenia, which could also serve as a drug target for treating cognitive symptoms ...
Study conducted in collaboration with the Neuroregeneration Institute at McLean HospitalAutologous neuronal cell therapy for ...
When Ron Cohen, M.D., CEO of Oryon Cell Therapies, recently dug into the company’s Parkinson’s disease data, he told Fierce ...
New treatments for neurodegenerative diseases like Alzheimer's, Parkinson's, and motor neuron disease (MND) could be unlocked ...
Oryon Cell Therapies’ lead cell therapy is an autologous treatment designed to replace dopaminergic neurons in patients with ...
Scientists have uncovered a hidden “death switch” in the brain that may be driving Alzheimer’s disease—and even found a way ...
Researchers say discovery could establish the basis for a novel, tandem biomarker-peptide therapeutic approach to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results